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Abstract
Rationale—Anxiety during pregnancy has been linked to adverse maternal health outcomes, 
including postpartum depression (PPD). However, there has been limited study of biological 
mechanisms underlying behavioral predictors of PPD during pregnancy.
Objectives—Considering the shared etiology of chronic stress amongst antenatal behavioral 
predictors, the primary goal of this pilot study was to examine associations among stress-related 
physiological factors (including GABA-ergic neurosteroids) and stress-related behavioral indices 
of anxiety during pregnancy.
Methods—Fourteen nulliparous women in their second trimester of a singleton pregnancy 
underwent speech and mental arithmetic stress, following a two-week subjective and objective 
recording of sleep-wake behavior.
Results—Lower cortisol, progesterone, and a combined measure of ALLO + pregnanolone 
throughout the entire stressor protocol (area under the curve, AUC) were associated with greater 
negative emotional responses to stress, and lower cortisol AUC was associated with worse sleep 
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quality. Lower adrenocorticotropic hormone was associated with greater anxious and depressive 
symptoms. Stress produced paradoxical reductions in cortisol, progesterone and a combined 
measure of allopregnanolone + pregnanolone, while tetrahydrodeoxycorticosterone levels were 
elevated.
Conclusions—These data suggest that cortisol, progesterone and ALLO + pregnanolone levels 
in the second trimester of pregnancy are inversely related to negative emotional symptoms and the 
negative impact of acute stress challenge appears to exert its effects by reducing these steroids to 
further promote negative emotional responses.
Keywords
Pregnancy; Anxiety; Postpartum Depression; Cortisol; Stress; Sleep; neurosteroids; 
Allopregnanolone (ALLO)
Introduction
Maternal mood and anxiety disorders during pregnancy have been linked to postpartum 
depression (PPD) (O'Hara 1996; O'Hara and Wisner 2014), which is estimated to affect 10% 
to 15% of mothers of childbearing age (Gavin et al. 2005; Gaynes et al. 2005; O'Hara 1996). 
Results of meta-analytic reviews have suggested several factors that may be strongly 
associated with increased risk for the development of depression during pregnancy and PPD, 
many of which may be identified early in pregnancy, including a history of chronic stress 
(O'Hara 1996; O'Hara and Wisner 2014; Verreault et al. 2014), and anxious and depressive 
symptoms during pregnancy (O'Hara 1996; O'Hara and Wisner 2014; Verreault et al. 2014). 
In addition, disturbed sleep has been associated with both depressed mood (Jomeen and 
Martin 2007; Okun et al. 2013; Skouteris et al. 2008) and stress during pregnancy (Okun et 
al. 2013), and has also been shown to be a potential predictor of depressive mood 
postpartum (Bei et al. 2010; Goyal et al. 2009; Okun et al. 2009). However, there has been 
limited study of the biological mechanisms underlying the relationships among chronic 
stress, sleep disturbances and perinatal mood and anxiety symptoms.
Perhaps most relevant to the interaction among chronic stress, sleep disturbance, and 
perinatal depression symptomatology, may be the joint stress-induced activation of the 
hypothalamic-pituitary-adrenal (HPA) axis, and progesterone (PROG)-derived gamma-
amino-butyric acid (GABA)-ergic neurosteroids, each of which has been implicated in 
reproductive mood disorders (Girdler et al. 2001; Segebladh et al. 2013), including PPD 
(Nappi et al. 2001; Nierop et al. 2006).
Neuroactive steroids such as the progesterone (PROG) metabolites 3α,5α-3-
hydroxypregnan-20-one (3α,5α–THP; allopregnanolone) and 3α,5β-3-hydroxypregnan-20-
one (3α,5β–THP; pregnanolone), and the deoxycorticosterone (DOC) metabolite 3α,
5α-3,21-dihydroxypregnan-20-one (tetrahydrodeoxycorticosterone; THDOC) are powerful 
endogenous positive modulators of GABAA receptors with antidepressant, anxiolytic, and 
sedative properties (Bitran et al. 1995; Crawley et al. 1986; Reddy 2006). These GABAergic 
neurosteroids, with cortisol, may therefore represent potential candidate mechanisms of PPD 
risk, since they each are stress responsive, are mutually regulatory during stress (Crowley 
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and Girdler 2014; Mody and Maguire 2011), and are implicated in the development of both 
PPD and insomnia (Basta et al. 2007; Schiller et al. 2014; Teran-Perez et al. 2012).
To date, no studies have examined stress-induced ALLO, pregnanolone, or THDOC in 
pregnancy or concurrent indicators of HPA axis activation [e.g., adrenocorticotrophic 
hormone (ACTH), cortisol] and their relationship to mood and anxiety in pregnancy. One 
potential pathway underlying the relationship among GABAergic neurosteroids, HPA axis 
activity, and the development of PPD may reside in their relationship to stress-related 
behavioral regulation during pregnancy. Considering the biopsychosocial challenges 
incurred during the transition to motherhood, pregnancy itself might be conceptualized as a 
chronic stressor and therefore an apt model for the investigation of physiological and 
behavioral markers of stress that may be predictive of postpartum mood dysregulation.
Using the perinatal first and second trimester as a natural longitudinal model of chronic 
stress, we examined the relationships among stress reactive neurosteroids, HPA axis 
hormones, and stress-related behavioral factors (sleep disturbances, emotional responses to 
stress). The primary goal of this pilot study was to examine the associations among daytime 
physiological stress reactivity measures and stress-related behavioral indices of anxiety 
during pregnancy in order to identify potential stress-related biomarkers of risk as a 
preliminary step to developing a biobehavioral predictive model of PPD that might be tested 
in future research.
Methods
Participants
Fourteen nulliparous women in the second trimester of a singleton pregnancy were recruited 
from the community using flyers, email listserv, and local advertisements. Recruitment was 
targeted so that laboratory testing could be conducted during the second trimester of 
pregnancy (22–24 weeks gestation). Exclusion criteria included: age < 18 years or > 45 
years; multiparity; non-singleton pregnancy; current use of antidepressants, anti-anxiety 
medications, mood-stabilizers, psychotropic medications, progesterone treatment, or sleep 
medications (prescription or over the counter); current use of tobacco, alcohol, recreational 
drugs, or steroids; current or recent history (within the last 6 months) of a depressive 
disorder; current or recent history (within the last three years) of anxiety disorders, or eating 
disorders; any history of schizoaffective disorder, bipolar disorder, or neurodevelopmental 
disorder, confirmed by the Structured Clinical Interview for DSM-IV disorders (SCID); 
chronic health problems (obtained via self-report) that may affect sleep, endocrine, or 
cardiovascular function including diagnosed obstructive sleep apnea, diagnosed restless legs 
syndrome, cancer, pre-gestational diabetes, chronic hypertension (documented or taking 
medication for hypertension), gestational hypertension, preeclampsia, or anemia; medical 
high risk pregnancy, as determined from obstetrics clinic assessment; a body mass index of 
> 40kg/m2 just prior to the pregnancy; and other medical issues that would preclude safe 
participation in the study.
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Screening and Enrollment
From July 2014 through November 2014, 57 women were screened via telephone for 
inclusion into the study. Of these, 32 (56.14%) met initial screening criteria, 25 (43.86%) 
did not meet initial screening criteria. Of the 32 women who met the initial screening 
criteria, four did not meet eligibility criteria following an in-person enrollment session 
involving a medical screen, and a psychiatric interview (three for medical histories not 
reported during the phone screen and one for a recent history of anxiety disorder); seven 
were no longer interested; and four could not be scheduled due to conflicts. In total, 17 
women were enrolled into the laboratory-based study protocol. Fourteen women with 
complete assay data for the laboratory-based study protocol are included in the present 
report.
Psychiatric History Assessment and Enrollment Session
All procedures were approved by the university institutional review board and all 
participants underwent informed consent prior to the initiation of the enrollment session. 
During the enrollment session, participants were evaluated for past depressive disorders 
(e.g., major depressive disorder, minor depressive disorder, adjustment disorder with 
depressive features, etc.), anxiety disorders (e.g., panic disorder, generalized anxiety 
disorder, etc.) and post-traumatic stress disorder (PTSD) using the SCID (Spitzer et al. 
1995). Women with DSM-IV (American Psychiatric Association, 1994) Axis I disorders, 
current (within six months) depression, recent (within three years) Axis I disorders, and/or 
any history of bipolar, schizoaffective, and neurodevelopmental disorders at study 
enrollment were excluded. To create clinically and conceptually meaningful categories, all 
histories of depressive disorders were categorized as ‘any depressive disorder’ and all 
histories of anxiety disorders were categorized as ‘any anxiety disorder.’ A urine pregnancy 
test (SA Scientific, San Antonio) was conducted during the enrollment session to confirm 
pregnancy. Also administered during the enrollment session were the Edinburgh Postnatal 
Depression Scale (EPDS); the Speilberger State Trait Anxiety Inventory (STAI), trait 
version; and a questionnaire to assess demographic and socioeconomic information.
Sleep Recording
Following the enrollment session, participants were provided an actiwatch spectrum plus 
(Philips Respironics, Bend Oregon) and sleep diary for in-home recording of sleep-wake 
behavior for a period of two weeks. In addition to filling out the prospective sleep diaries 
daily, morning and night, participants were instructed to wear the actiwatch continuously on 
their non-dominant wrist, only removing the device should it become immersed in water. 
Using an accelerometer to record movements of the arm over time, the actiwatch provides a 
reliable measure of sleep-wake behavior (Cole et al. 1992) that has been validated against 
polysomnography (Marino et al., 2013). In order to increase accuracy of scoring, 
participants were asked to press an event marker button on the watch to indicate (1) when 
the participant intended to initiate sleep at night (e.g., when they turn the lights off with the 
intention of going to sleep); (2) when the participant woke in the morning with the intention 
to get out of bed; and (3) before and after any daytime naps. All data was checked against 
the sleep diaries for scoring of sleep-wake intervals. Data were collected in one-minute 
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epochs, scored for periods of wake and sleep using a standard Philips Respironics Actiware 
software algorithm. Average sleep onset latency (SOL), or the time (in minutes) from 
bedtime to sleep onset, was subjectively measured via sleep diaries and objectively 
measured via actigraphy. In addition, average wake after sleep onset (WASO), or the sum 
total (in minutes) of wake times from sleep onset to final morning wake time; and average 
sleep fragmentation index, or the amount of movement/restlessness in a sleep period (where 
a higher index indicates more restless sleep) was objectively measured via actigraphy. At the 
end of the sleep recording period, participants completed the Pittsburgh Sleep Quality 
Inventory (PSQI) as a measure of overall sleep quality.
Stress Testing Laboratory Session
Following the sleep recording period, each subject participated in a single laboratory session 
that was scheduled between 3:00 p.m. and 5:00 p.m. To ensure that participants were 
hydrated prior to the laboratory session, each participant was asked to consume eight, eight-
ounce glasses of water on the day prior to sampling, and at least five eight-ounce glasses and 
a low fat breakfast and lunch the day of testing (confirmed via self-report diary). Participants 
were asked to refrain from over-the-counter medications 24 hours prior to testing; and from 
caffeine, exercise and alcohol the day of testing (confirmed via interview at study visit). 
Participants who had been ill within seven days of testing or who had fewer than six hours 
of sleep the previous night were rescheduled.
As illustrated in figure 1, our laboratory protocol consisted of the following events in fixed 
order: (1) instrumentation and venipuncture (that included the insertion of an indwelling 
catheter for serial blood sampling); (2) venipuncture recovery (20 min); (3) speech 
preparation (2 min) consisting of silent preparation of speech; (4) speech task (3 min) where 
the participant was asked to speak about a recent interpersonal stressor [randomly selected 
(to prevent rehearsal) by research staff from a list of three potential topics provided by the 
participant] in front of a female evaluator holding a microphone attached to an audio 
recorder. Participants were told that the evaluator was trained in behavioral analysis and that 
the audio recording of their speech would be later replayed to research staff for analysis of 
speech characteristics; (5) paced auditory serial addition task (PASAT, 9 min.) where 
participants were asked to listen to a tape recording with numbers from 1 to 9 and to add 
each number presented to the immediately preceding number, stating the answer aloud. The 
PASAT is comprised of four series of progressively shorter inter-digit intervals (Tombaugh 
2006); (6) post-stress recovery (40 min). During the venipuncture recovery period, the 
participant rested alone quietly in a comfortable chair. A curtain shielded the catheter and 
the blood sampling from the participant’s view. Cardiovascular measures [heart rate (HR), 
systolic blood pressure (SBP), and diastolic blood pressure (DBP)] were collected during the 
laboratory stress testing paradigm using automated equipment [Suntech Exercise BP 
monitor, Model 4240 (SunTech Medical Instruments, Inc., Raleigh, NC)] at the following 
intervals: (1) every two minutes during the last 10-min of the venipuncture recovery period 
(that constituted the pre-stress baseline comparison period); (2) at the beginning of the 
speech preparation period; (3) at the beginning and at minute two of the speech task; (4) 
every two minutes of the PASAT task; (5) every five minutes of the first 20 minutes of the 
post-stress recovery period. These measures were then averaged to obtain a mean speech 
Crowley et al. Page 5
Psychopharmacology (Berl). Author manuscript; available in PMC 2017 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
preparation, speech, and PASAT task value for each cardiovascular measure. Blood samples 
were collected from an indwelling catheter at the following intervals: (1) for cortisol: end of 
venipuncture recovery (min 20) and again 10, 20, 30, and 40 minutes post-stressor 
completion; (2) for ACTH: end of venipuncture recovery (min 20), immediately following 
stressor completion, and 10 and 20 minutes post-stressor completion; (3) Progesterone 
(PROG) and neurosteroids [ALLO, Pregnenolone, Pregnanolone, 3α,5β-THDOC 
(THDOC)]: end of venipuncture recovery period (min 20), minute two of the speech task, 
immediately following stressor completion, and 10, 20, 30, and 40 minutes post-stressor 
completion.
At the end of the stressor period, but before beginning post-stress recovery, participants 
rated their emotional responses to the stressor battery. Using a Likert scale ranging from 0 
(“not at all”) to 10 (“extremely”), participants indicated the extent to which the stressors 
caused them to feel anxious, overwhelmed, or worried.
Neuroendocrine Assays
Blood for cortisol, PROG, and neurosteroids was collected into serum-separating (SST) 
tubes, and left at room temperature for 30 minutes. Samples were spun at 3,000 rpm for 10 
minutes at room temperature (18°C) and supernatant (serum) was aliquoted into 2mL tubes 
and frozen at −80°C until assayed. Blood for ACTH was collected into EDTA Vacutainer 
tubes that were kept on ice. Immediately after blood draw, tubes for ACTH were centrifuged 
at 3000 rpm for 10 minutes at 4°C. Supernatant (plasma) was aliquoted into tubes, rapidly 
frozen, and maintained at −80°C until assayed.
Serum levels of cortisol were determined by radioimmunoassay (RIA) using commercial 
kits from ICN pharmaceuticals (Hampshire, United Kingdom). The sensitivity of the assay 
is excellent at 0.07µg/dL. The specificity of the RIA for cortisol is high, showing only 
0.05%–2.2% cross-reactivity with most similarly structured compounds. Plasma ACTH was 
determined using RIA techniques from commercially available kits (Nichols Institute 
Diagnostics). The sensitivity of this assay is high at 1 pg/ml, and the selectivity is excellent 
showing only 0.0%–0.02% cross-reactivity with steroid compounds. The specificity of the 
antiserum for PROG is very high, showing only 0.01%–2.5% cross-reactivity with other 
steroid compounds.
To check for cross-reactivity of cortisol and PROG with neuroactive steroids in our sample 
of pregnant women, a competition curve using seven concentrations (4000ng/ml to 1ng/ml) 
of four steroids (ALLO, THDOC, pregnanolone, PROG) was conducted in both the cortisol 
and PROG RIAs. Little to no cross-reactivity of the steroids was detected in either assay. In 
the cortisol assay, none of the steroid concentrations measured more than 0.2% of the 
cortisol concentration. In the PROG assay, none of the steroid concentrations measured 
more than 0.2% of the PROG concentration, except for ALLO at 4000ng/ml that measured 
1.45%.
Neurosteroids were measured in serum by Gas Chromatography – Mass Spectrometry 
(GCMS) following purification by solid phase extraction, as previously described (Girdler et 
al. 2012; Porcu et al. 2009).
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Data Reduction and Analysis
Sensitivity analyses were used to identify extreme outliers prior to data analysis, defined as 
values three or more standard deviations above or below the mean. For this sample, one 
outlier was detected for ACTH, and as such, the outlier was removed from the ACTH 
dataset prior to analysis. The stereoisomers 3α,5α-THP (ALLO) and 3α,5β-THP 
(pregnanolone) have similar potency and efficacy as positive modulators of GABA action at 
GABAA receptors (Majewska et al. 1986; Morrow et al. 1990) and the extent of the stress-
induced decrease, from baseline, elicited by our stressor protocol was similar (table 3). 
Therefore, in line with previous work (Uzunova et al. 1998), in addition to ALLO and 
pregnanolone, we have presented the combined concentrations of these neuroactive steroids 
under the acronym 3α,5α + 3α,5β–THP for statistical analyses of significance. Indeed, 
previous work has shown that cerebral spinal fluid (CSF) measures of this combined value 
(3α,5α + 3α,5β–THP) are significantly inversely associated with depression severity and 
also significantly increased following effective treatment with fluoxetine or fluvoxamine in 
unipolar depressed patients (Uzunova et al. 1998). Descriptive statistics (means, SD’s, 
proportions) were used to describe demographic and behavioral characteristics of the study 
population. For each cardiovascular measure, reactivity was defined as the difference 
between mean stress level and mean baseline level. One participant was missing values for 
cardiovascular data due to equipment failure. For each neuroendocrine measure, as 
described elsewhere (Klatzkin et al. 2006a; Pruessner et al. 2003), our primary analyses 
involved calculation of area under the curve with respect to ground (AUCg), which includes 
neuroendocrine values integrated across baseline rest, stress, and stress recovery periods, 
and is therefore an indicator of overall neuroendocrine status. Secondarily, we also 
examined neuroendocrine stress reactivity, which was defined as the difference between 
baseline level and the post-stress time point associated with the greatest change from 
baseline (whether increase or decrease). Consequently, stress-induced levels were measured 
for PROG and all neurosteroids, at 10 minutes post-stressor completion, for ACTH at 20 
minutes post-stressor completion, and for cortisol at 40 minutes post-stressor completion. 
For the neuroendocrine data, two participants were missing recovery values due to inability 
to obtain the blood samples. Paired t-tests were used to confirm a significant effect of the 
modified TSST on cardiovascular and neuroendocrine measures. Where significant (from 
baseline) stress values were obtained, we conducted correlational analyses with behavioral 
measures. All p values reported are 2-sided with an alpha level of 0.05. All statistical 
analyses were performed using SAS 9.3 (SAS Institute, Inc., Cary, North Carolina).
Results
Participant Characteristics
As reflected in Table 1, the mean age for the participants was 29.9 +/− 4.7, and the mean 
gestational stage at study enrollment was 21.0 ± 1.0 weeks. Participants were generally well-
educated with ~79% of the sample having acquired a master’s degree or higher. The mean 
EPDS and STAI scores for our sample of women (mean EPDS: 4.1 ± 3.4; mean STAI: 30.0 
± 4.0), were at or below the normative range for women in the second trimester of 
pregnancy (Bergink et al. 2011; Gunning et al. 2010). Baseline cortisol and PROG 
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concentrations during the second trimester of pregnancy were consistent with expected 
values (Soldin et al. 2005).
Associations among Neuroendocrine Status and Behavioral Measures
As shown in table 2, lower cortisol AUCg was associated with increased sleep disturbances 
(SOL: r = −0.64, p = 0.03; WASO: r = −0.85, p ≤ 0.001; fragmentation index: r = −0.66, p = 
0.02) and worse self-reported sleep quality (PSQI: r = −0.74, p ≤ 0.001), in addition to 
increased negative emotional responses to stress (anxiety in response to the PASAT task: r = 
−0.69, p = 0.01; see Figure 2 for relationship of Cortisol AUCg to WASO and PASAT 
anxiety). Lower ACTH AUCg was associated with depressive (EPDS: r = −0.58, p = 0.04) 
and anxious (STAI: r = −0.67, p = 0.01) symptoms in pregnancy. Lower PROG AUCg was 
associated with increased anxious (STAI: r = −0.66, p = 0.02) symptoms in pregnancy in 
addition to increased negative emotional responses to stressor tasks (feeling worried and 
overwhelmed in response to the speech task (r’s = −0.60, p’s ≤ 0.05) and feeling worried in 
response to the PASAT task (r = −0.66, p = 0.02). Lower ALLO AUCg was associated with 
more negative emotional responses to the PASAT task (feeling overwhelmed: r = −0.71; p = 
0.01), and a trend was observed for lower ALLO AUCg to predict worse sleep quality 
(diary-measured SOL: r = −0.49, p = 0.10; PSQI: r = −0.52, p = 0.08). Lower ALLO + 
pregnanolone (3α,5α + 3α,5β–THP) AUCg was associated with a more negative emotional 
response to the PASAT task (feeling overwhelmed: r = −0.63; p = 0.03). No significant 
relationships were observed among pregnanolone AUCg and behavioral measures (data not 
shown). No other significant relationships were observed among neuroendocrine measures 
and behavioral indices of anxiety.
Overall Efficacy of the Stress Protocol
As shown in table 3, SBP, DBP, and HR all significantly increased in response to the 
stressor task [t (12) = 16.4, 11.4, and 10.0, p’s < 0.001, respectively]. For the 
neuroendocrine measures, we observed a significant decrease from baseline to stressor for 
cortisol [t (12) = −2.2, p = 0.05], PROG [t (14) = −2.62, p = 0.02], and the combined ALLO 
+ pregnanolone measure [t (14) = −2.3, p = 0.04] (see Figure 3). While 3α,5α-THDOC 
could not be detected in the assay, a significant increase in 3α,5β-THDOC was observed 
from baseline to stressor [t (14) = 3.6, p = 0.003] (see Figure 4). There was no effect of 
stress on pregnanolone levels (data not shown). No other significant changes from baseline 
to stressor were observed for the neuroendocrine measures.
Discussion
Our findings indicate that integrated levels of GABAergic neurosteroids and HPA axis 
hormones (integrated across rest, stress and stress recovery periods) may regulate 
fundamental processes underlying the core symptoms of perinatal mood and anxiety 
disorders, and that these relationships are apparent even during the second trimester of 
pregnancy. Specifically, we observed that lower integrated cortisol, ACTH, PROG, and the 
combined ALLO + pregnanolone value were associated with increased anxiety-related 
emotional responses to stress, worse sleep quality, and increased symptom severity in 
second trimester pregnant women. This is consistent with previous research indicating that 
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lower stress-induced PROG and ALLO levels may predict symptom severity in women with 
menstrually-related mood disorders (Klatzkin et al. 2006b).
One plausible mechanism by which these biological variables may increase risk for PPD is 
by altering sensitivity to environmental stressors, such as sleep disturbances during 
pregnancy, and in this way, increasing risk for the development of psychopathology. Given 
the bi-directional relationship between sleep disruption and affective dysregulation (Krystal 
2012; Slavich and Irwin 2014), the identification of sub-threshold insomnia symptoms (e.g., 
stress-related sleep disturbances) during pregnancy may help to inform preventative 
treatment efforts that could significantly impact the clinical course of postpartum depression 
symptomatology.
Remarkably, we also observed a reversal of the “classic” stress response to a laboratory-
based psychosocial stressor (Dickerson and Kemeny 2004) in several neuroendocrine 
measures (namely cortisol, ACTH, PROG, and the combined ALLO + pregnanolone 
measure). However, the psychosocial laboratory challenge was an effective stressor for 
pregnant women in their second trimester of pregnancy as evidenced by significant 
increases, from baseline, in the cardiovascular measures that reflect sympathetic/autonomic 
function. Our cardiovascular results are in line with results from other studies conducted in 
pregnant women during the third trimester of pregnancy (Christian 2012; De Weerth et al. 
2007; Monk et al. 2000), which indicates that the cardiovascular response to stress appears 
to be maintained during pregnancy (albeit attenuated; Matthews and Rodin 1992).
Both animal and human studies suggest that maternal HPA axis responses to stress are 
markedly suppressed in late pregnancy (e.g., 3rd trimester; Brunton and Russell 2008; 
Christian 2012), but this is the first study to suggest this may be true in second trimester as 
well. It has been suggested that this mechanism not only serves to promote appropriate 
metabolic adaptations necessary for a successful pregnancy outcome, but to also minimize 
fetal exposure to excessive levels of glucocorticoids in utero that may contribute to 
detrimental fetal programming (Herrera 2000). While several mechanisms have been 
proposed to explain the pregnancy-related adaptations in the brain that underpin HPA axis 
hypo-responsiveness during pregnancy, evidence from animal models suggests that ALLO 
may play a critical role in suppressed HPA axis responses to stress in pregnancy (Brunton et 
al. 2009; Brunton and Russell, 2011).
However, given our observations of stress-induced increases in 3α,5β-THDOC, an 
alternative, though not mutually exclusive possibility, is one of a differential neurosteroid 
metabolism in response to acute stress in women during pregnancy. During acute stress, 
PROG and deoxycorticosterone (DOC) undergo sequential metabolic reduction by 5α-and 
5β-reductase and 3α- hydroxysteroid dehydrogenase (3α-HSD) to form ALLO, 
Pregnanolone, and 3α,5α- and 3α,5β-THDOC (Rupprecht and Holsboer 1999). To date, the 
physiological importance of 3α,5β-THDOC is not well studied, however, it is clearly 
GABAergic (Morrow et al. 1990) and there is substantial evidence that 3α,5α-THDOC 
participates in the HPA axis response to acute stress in rodents (Morrow et al. 1995; Purdy 
et al. 1991; Reddy and Rogawski 2002). It may be possible that the clinical relevance of 3α,
5β-THDOC to psychopathology is related to its elevation following stress that associates 
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with the dampening of the HPA axis stress response indicated not only by the reduction in 
cortisol that we observed but also by the reduction in the progesterone-derived neuroactive 
steroids, since the adrenals represent the primary source of circulating neuroactive steroids 
in response to stress (O'Dell et al. 2004; Purdy et al. 1991).
To the extent that lower ALLO and pregnanolone concentrations, especially following 
stress, are associated with diminished capacity to negatively modulate the HPA axis and 
facilitate its recovery following stress exposure (Guo et al. 1995; Patchev et al. 1996), then 
the blunted ALLO + pregnanolone stress response that was observed in our study sample 
may be one mechanism that may increase vulnerability to stress and stress-related illness 
(Crowley and Girdler 2014), including PPD. This may be particularly true for those women 
with a history of depressive illness, which is highly associated with chronic stress (Kendler 
et al. 2000; McGuffin and Rivera 2015), and in whom we previously observed a blunted 
ALLO response to mental stress relative to never depressed women (Klatzkin et al. 2006b). 
This is also consistent with data from animal models of chronic stress and diminished 
neurosteroid availability/synthesis (Bortolato et al. 2011; Dong et al. 2001; Guidotti et al. 
2001; Matsumoto et al. 2005; Serra et al. 2000; Serra et al. 2005). Although only two 
women in our sample had a history of depression, post-hoc descriptive review of the data 
indicated that they had lower ALLO + pregnanolone AUCg levels coupled with higher β-
THDOC levels than those without a history of depression.
Why we observed a significant stress-induced increase, from baseline, in 3α,5β-THDOC, yet 
blunting of the neuroendocrine output across the stressor protocol in other neuroendocrine 
measures, including cortisol, ACTH, PROG, and the combined ALLO + pregnanolone 
value, (which were inversely associated with negative emotional stress responses), is 
intriguing. One possible explanation is that the extent of susceptibility to affective 
dysregulation following stress may depend on the maintenance of an appropriate balance of 
neuroactive steroids, HPA axis hormones, and/or perhaps other neuromodulatory factors 
(e.g. pro-inflammatory cytokines), that have also been linked to affective regulation (Raison 
et al. 2006).
The hypothesis that stress- induced affective dysregulation may be influenced by the balance 
of neuroactive steroids (Porcu et al. 2006), may be of particular relevance to our finding 
that, concurrent with a stress-induced decrease in several neuroendocrine measures, we also 
observed a stress-induced increase in 3α,5β-THDOC. Using the concept of pregnancy as a 
model of chronic stress, and capitalizing on the opportunity to study challenges to the 
neuroendocrine system in a natural model of HPA axis suppression (e.g., pregnancy), our 
results suggest that, during pregnancy, 3α,5β-THDOC is not downregulated during stress as 
are other GABAergic neurosteroids. Considering the evidence that the HPA axis is blunted 
in pregnancy, and our finding of general neuroendocrine suppression, it is possible that 
stress-induced synthesis of 3α,5β-THDOC and/or its precursor, DOC may involve factors 
outside of adrenal sources. This hypothesis is in line with previous research in non-human 
primates which has shown that following dexamethasone suppression of the HPA axis and 
subsequent ACTH administration, DOC levels fail to change in response to exogenous 
ACTH (Porcu et al. 2006). Though we did not observe any significant relationships between 
3α,5β-THDOC levels and behavioral measures in our sample, the predictive power of 
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deoxycorticosterone-derived neuroactive steroids such as THDOC in PPD may rest in their 
relationship to other GABAergic neurosteroids, or other neuroendocrine factors. This 
question will require further longitudinal investigation.
Although the strengths of our study consist of a highly novel study design including 
prospective assessment of subjectively and objectively measured sleep-wake behavior, a 
laboratory-based psychosocial stress paradigm for the assessment of daytime stress 
reactivity, and measurement of stress-reactive GABA-ergic neurosteroids, this study is not 
without its limitations. First, the analyses reported here must be considered preliminary 
based on our small sample size, and the nature of this study as pilot work that is meant to 
inform future research. Moreover, compared to a clinical sample, our women, on average, 
exhibited mild depressive and anxious symptoms (mean EPDS score = 4.1 ± 3.4; mean 
STAI score = 30.0 ± 4.0), that were at or below the normative range for women in the 
second trimester of pregnancy (Bergink et al. 2011; Gunning et al. 2010). However, it is 
interesting that these women displayed sleep characteristics that were clinically significant 
(Natale et al. 2015), particularly with regards to stress-related sleep disturbances such as 
prospective diary assessed sleep onset latency. Therefore, while our results may not be 
generalizable to a clinical population, our study targets an important question regarding the 
fundamental processes linking behavioral predictors in pregnancy to perinatal affective 
dysregulation. Using a conceptual model of pregnancy as a chronic stressor, particularly for 
first-time mothers, further investigation in a clinical population may provide more insight 
with regards to a “tipping point” where stress-related physiological changes may be 
associated with increased risk for disease. Although to our knowledge, we are the first to 
investigate relationships among neuroendocrine stress reactivity (including neurosteroids) 
and behavioral indices of anxiety in women during the second trimester of pregnancy, a 
second limitation of the present study is presented in our sample enrollment, which 
displayed some heterogeneity (e.g., psychiatric history characteristics) that may have 
influenced our measurements. Nonetheless, the results of the present investigation 
demonstrate the feasibility of this protocol in pregnant women and provide general proof of 
concept for potential biomarkers of risk that may bridge the link between behavioral 
symptoms in pregnancy and risk for PPD. Specifically, our findings that blunted cortisol, 
PROG, and ALLO + pregnanolone were associated with worse sleep and more anxiety 
related emotional responses to stress suggests that these neuroendocrine factors may serve as 
mediators in the link between affective disturbance in pregnancy and the development of 
PPD. Clearly a larger sample and a longitudinal design would be needed to test whether this 
profile represents a “biosignature” of risk in pregnancy for the development of PPD, but the 
results of this study would support such research.
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Figure 1. 
Schematic representation of stress testing protocol: aCardiovascular measures [heart rate 
(HR), systolic blood pressure (SBP), and diastolic blood pressure (DBP)] were collected (1) 
every two minutes during the last 10-min of the venipuncture recovery period; (2) at the 
beginning of the speech preparation period; (3) at the beginning and at minute two of the 
speech task; (4) every two minutes of the PASAT task; and (5) every five minutes of the 
first 20 minutes of the post-stress recovery period. These measures were then averaged to 
obtain a mean speech preparation, speech, and PASAT task value for each cardiovascular 
measure. bBlood for cortisol was collected at the end of venipuncture recovery and again 10, 
20, 30, and 40 minutes post-stressor completion. cBlood for adrenocorticotrophic hormone 
(ACTH) was collected (1) at the end of venipuncture recovery; (2) immediately following 
stressor completion (after the PASAT task); and (3) 10 and 20 minutes post-stressor 
completion. Blood for dprogesterone (PROG) and neurosteroids [ALLO, Pregnanolone, 3α,
5β-THDOC (THDOC)] was collected (1) at the end of venipuncture recovery period; (2) 
minute two of the speech task; (3) immediately following stressor completion (after the 
PASAT task); and (4) 10, 20, 30, and 40 minutes post-stressor completion.
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Figure 2. 
Scatterplot and regression line reflecting Pearson correlation (r) of Cortisol AUGG and (A) 
mean actigraphy-measured wake after sleep onset (WASO) duration (in minutes); and (B) 
anxiety in response to the Paced Auditory Serial Addition Task (PASAT)
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Figure 3. 
Time course of the ALLO + pregnanolone combined measure stress response in second 
trimester pregnant women, measured via GC-MS. Data represent mean ± SEM as a function 
of time across the task. aSample taken during minute 2 of the speech task. bSample taken 
immediately following the PASAT task. **p ≤ 0.05
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Figure 4. 
Time course of 3,5β–THDOC stress response in second trimester pregnant women, 
measured via GC-MS. Data represent mean ± SEM as a function of time across the 
task. aSample taken during minute 2 of the speech task. bSample taken immediately 
following the PASAT task. *p ≤ 0.01; ** p ≤ 0.05
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Table 1
Characteristics of study participants
Participants, n 14
Age, years (mean ± SD) 29.9 ± 4.7
Gestational stage at study enrollment (mean ± SD) 21.0 ± 1.0
Race
  White, n (%) 9 (64.3)
  Other, n (%) 5 (35.7)
Education
  College degree or lower, n (%) 3 (21.4)
  Master’s n (%) degree, n (%) 9 (64.3)
  Professional Degree or Doctorate, n (%) 2 (14.3)
Family income (annually)
  < $75,000/year, n (%) 6 (42.9)
  $75,000/year, n (%) 8 (57.1)
Depression History
  yes, n (%) 2 (14.3)
  no, n (%) 12 (85.7)
Anxiety History
  yes, n (%) 1 (7.1)
  no, n (%) 13 (92.9)
EPDS 4.1 (3.4)
STAI (Trait Version; mean ± SD) 30.0 ± 4.0
PSQI (mean ± SD) 5.5 ± 3.0
SOL AverageDiary (mean ± SD) 26.5 ± 16.6
SOL AverageActigraphy (mean ± SD) 10.0 ± 5.85
WASO AverageActigraphy (mean ± SD) 48.4 ± 19.5
Sleep Fragmentation Index AverageActigraphy (mean ± SD) 28.0 ± 9.9
Baseline Cortisol ng/mL (mean ± SD) 191.7 ± 96.5
Baseline ACTH pg/mL (mean ± SD) 99.1 ± 46.3
Baseline PROG ng/mL (mean ± SD) 87.4 ± 30.0
Baseline pregnenolone pg/mL (mean ± SD) 637.4 ± 179.8
Baseline ALLO (3α,5α–THP) pg/mL (mean ± SD) 551.8 ± 176.7
Baseline pregnanolone (3α,5β–THP) pg/mL (mean ± SD) 339.4 ± 146.7
Baseline 3,5β–THDOC pg/mL (mean ± SD) 299.0 ± 124.8
Baseline 3α,5α + 3α,5β–THP pg/mL (mean ± SD) 891.2 ± 285.9
EPDS = Edinburgh Postnatal Depression Scale; STAI = Speilberger State-Trait Anxiety Inventory, trait version; PSQI = Pittsburgh Sleep Quality 
Index; SOL = sleep onset latency (in minutes); WASO = wake after sleep onset (in minutes); ACTH = adrenocorticotrophic Hormone; PROG = 
progesterone; ALLO = allopregnanolone; THDOC = allotetrahydrodeoxycorticosterone
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Table 3
Stress-reactive physiological measurements in second trimester pregnant women.
Mean change (+/− SEM)
from baseline to stressor
p Value
Neuroendocrine measures
Cortisol (ng/ml) −42.1 (19.3) 0.05
ACTH (pg/ml) −8.7 (4.6) 0.08
PROG (ng/ml) −12.3 (4.7) 0.02
Pregnenolone (pg/ml) −36.6 (35.0) 0.31
ALLO (3α,5α–THP) (pg/ml) −28.9 (28.4) 0.33
Pregnanolone (3α,5β–THP) (pg/ml) −38.5 (22.0) 0.10
3α,5α + 3α,5β–THP (ALLO + Pregnanolone) (pg/ml) −67.3 (28.8) 0.04
3α,5β–THDOC (pg/ml) 73.1 (20.3) 0.003
Cardiovascular Measures
Heart Rate (bpm) 10.0 (2.3) <0.001
Systolic Blood Pressure (mmHg) 16.4 (2.9) <0.001
Diastolic Blood Pressure (mm/Hg) 11.4 (1.9) <0.001
SEM = standard error of the mean; ACTH = Adrenocorticotrophic Hormone; PROG = Progesterone; ALLO = Allopregnanolone; THDOC = 
tetrahydrodeoxycorticosterone
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